Owen Cain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Owen Cain has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
AL Wilkinson
Centre for Liver and Gastrointestinal Research, University of Birmingham, UK
1 shared publication- Adam Shephard
Tissue Image Analytics Centre, Department of Computer Science, University of Warwick, Coventry, UK
1 shared publication Adrian Yoong
Department of Cellular Pathology, Birmingham Women's NHS Foundation Trust, Birmingham, UK
1 shared publication- Ahmed Mohamed Elsharkawy
Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
1 shared publication - Andre Boonstra
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
1 shared publication - Ann Driessen
Department of Pathology, University Hospital Antwerp (UZA), Antwerp University, Drie Eikenstraat 655, Edegem, 2650 Antwerp, Belgium
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Korean Liver Transplantation Society in Annals of Liver Transplantation
Standardised assessment of liver from donors with haemochromatosis
Cristine Brooke Pathirannehalage Don, Elijah Ablorsu, Matthew Armstrong, Owen Cain, Bobby V.M. Dasari. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.26.0011
- 10 September 2026
- Published by Korean Liver Transplantation Society in Annals of Liver Transplantation
Open AccessStandardised assessment of liver from donors with haemochromatosis
Cristine Brooke Pathirannehalage Don, Elijah Ablorsu, Matthew Armstrong, Owen Cain, Bobby V.M. Dasari. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.26.0011
- Open Access
- 31 August 2026
- Published by Elsevier in Biomedical Signal Processing and Control
- Vol. 129
CORE: A coarse-to-fine registration engine for multi-stain whole-slide images
- 31 August 2026
- Published by Elsevier in Biomedical Signal Processing and Control
- Vol. 129
Open AccessCORE: A coarse-to-fine registration engine for multi-stain whole-slide images
- 28 March 2026
- Published by Wiley in Histopathology
- Vol. 89 (5) , 886-891
Secondary changes in the peripheral liver due to kaposiform haemangioendothelioma in the hepatic hilum: a report of two transplant cases
Aims: Kaposiform haemangioendothelioma (KHE) is a rare vascular neoplasm of infancy and childhood that typically affects the soft tissues of the extremities; however, a variety of visceral sites have been reported. When KHE is located within the liver hilum, it may involve hilar structures and lead to secondary changes in the hepatic parenchyma. We report the histological changes in the explant livers of two patients transplanted for liver failure secondary to clinically unsuspected KHE at the hepatic hilum. Methods and results: Patient A initially presented with the signs and symptoms of liver failure at the age of 6. Despite extensive clinical work up, no aetiology was identified and she was diagnosed with ‘cryptogenic cirrhosis’. The patient underwent liver transplantation at age 23, and her explanted liver revealed a vasoformative tumour within the hilum surrounding branches of the portal vein. Immunohistochemistry confirmed a diagnosis of KHE. Her peripheral liver showed features of obliterative portal venopathy and nodular regenerative hyperplasia. There was no evidence of cirrhosis. Patient B presented at age 7 with obstructive features of liver failure. Based on imaging studies and initial liver biopsies, a diagnosis of ‘primary sclerosing cholangitis’ (PSC) was rendered. However, liver transplantation at age 11 revealed KHE at the hepatic hilum surrounding the common hepatic duct. The peripheral liver demonstrated biliary‐pattern cirrhosis with periductal fibrosis and ductular reaction, supporting a diagnosis of secondary sclerosing cholangitis rather than PSC. Conclusions: In conclusion, changes seen in peripheral liver biopsies can sometimes be a consequence of unsampled lesions at the liver hilum. KHE is a very rare example of this, but this scenario should be considered when liver biopsy findings do not correlate well with the clinical history.
- 28 March 2026
- Published by Wiley in Histopathology
- Vol. 89 (5) , 886-891
Secondary changes in the peripheral liver due to kaposiform haemangioendothelioma in the hepatic hilum: a report of two transplant cases
Aims: Kaposiform haemangioendothelioma (KHE) is a rare vascular neoplasm of infancy and childhood that typically affects the soft tissues of the extremities; however, a variety of visceral sites have been reported. When KHE is located within the liver hilum, it may involve hilar structures and lead to secondary changes in the hepatic parenchyma. We report the histological changes in the explant livers of two patients transplanted for liver failure secondary to clinically unsuspected KHE at the hepatic hilum. Methods and results: Patient A initially presented with the signs and symptoms of liver failure at the age of 6. Despite extensive clinical work up, no aetiology was identified and she was diagnosed with ‘cryptogenic cirrhosis’. The patient underwent liver transplantation at age 23, and her explanted liver revealed a vasoformative tumour within the hilum surrounding branches of the portal vein. Immunohistochemistry confirmed a diagnosis of KHE. Her peripheral liver showed features of obliterative portal venopathy and nodular regenerative hyperplasia. There was no evidence of cirrhosis. Patient B presented at age 7 with obstructive features of liver failure. Based on imaging studies and initial liver biopsies, a diagnosis of ‘primary sclerosing cholangitis’ (PSC) was rendered. However, liver transplantation at age 11 revealed KHE at the hepatic hilum surrounding the common hepatic duct. The peripheral liver demonstrated biliary‐pattern cirrhosis with periductal fibrosis and ductular reaction, supporting a diagnosis of secondary sclerosing cholangitis rather than PSC. Conclusions: In conclusion, changes seen in peripheral liver biopsies can sometimes be a consequence of unsampled lesions at the liver hilum. KHE is a very rare example of this, but this scenario should be considered when liver biopsy findings do not correlate well with the clinical history.
- Open Access
- 20 December 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101714
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells
- 20 December 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101714
Open AccessA liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells
- Open Access
- 1 June 2021
- Published by Taylor & Francis in Hepatic Medicine: Evidence and Research
- Vol. ume 13, 59-69
The Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics
Histology remains essential for the diagnosis and management of many disorders affecting the liver. However, the biopsy procedure itself is associated with a low risk of harm to the patient and cost to the health services; samples may not be adequate and are subject to sampling variation. Furthermore, interpretation often depends on the skill of the pathologist. Increasingly, new techniques are becoming available that are altering the indications for liver biopsy. Many diseases of the liver can be diagnosed and managed using serological and radiological techniques; the degree of fibrosis and fat can often be assessed by serological or imaging techniques and the nature of space occupying lesions defined by serology, imaging and use of liquid biopsy. However, these techniques, too, are subject to limitations: sensitivity and specificity is not always adequate for diagnosis or management; some techniques are expensive and often also require expert interpretation. Although there may be less need for liver biopsy today, histology remains the gold standard as well as an essential tool for the diagnosis and management of many conditions, especially where there are multiple pathologies, or where a diagnosis cannot or has not been made by alternative approaches. Until less invasive techniques become more reliable and accessible, liver histology will remain a key investigation.
- 1 June 2021
- Published by Taylor & Francis in Hepatic Medicine: Evidence and Research
- Vol. ume 13, 59-69
Open AccessThe Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics
Histology remains essential for the diagnosis and management of many disorders affecting the liver. However, the biopsy procedure itself is associated with a low risk of harm to the patient and cost to the health services; samples may not be adequate and are subject to sampling variation. Furthermore, interpretation often depends on the skill of the pathologist. Increasingly, new techniques are becoming available that are altering the indications for liver biopsy. Many diseases of the liver can be diagnosed and managed using serological and radiological techniques; the degree of fibrosis and fat can often be assessed by serological or imaging techniques and the nature of space occupying lesions defined by serology, imaging and use of liquid biopsy. However, these techniques, too, are subject to limitations: sensitivity and specificity is not always adequate for diagnosis or management; some techniques are expensive and often also require expert interpretation. Although there may be less need for liver biopsy today, histology remains the gold standard as well as an essential tool for the diagnosis and management of many conditions, especially where there are multiple pathologies, or where a diagnosis cannot or has not been made by alternative approaches. Until less invasive techniques become more reliable and accessible, liver histology will remain a key investigation.
- Open Access
P176 TSPAN6: a novel player in the microenvironment of primary liver cancers
Introduction Tetraspanins, a large family of membrane proteins, have been implicated in the regulation of the tumour microenvironment of a number of cancers. TSPAN6 has previously been shown to modulate the immune microenvironment in breast cancers via indirect interactions with tumour-infiltrating B cells; however, TSPAN6 has not been studied within the context of primary liver cancers, nor the human liver in general. Methods TSPAN6 mRNA expression was quantified in normal, chronically diseased and primary liver cancer tissues. The distribution and cellular localisation of TSPAN6 protein expression was explored utilising immunohistochemistry and multi-colour immunofluorescence. In addition, hepatocellular carcinoma (HCC) tumour samples were histologically scored on intensity and proportion of positivity for TSPAN6 and Kaplan-Meier curves were generated for patients with negative/low expression vs. positive TSPAN6 tumour expression. Results Transcriptional expression of TSPAN6 was comparable between normal and chronically diseased liver tissues, but was increased in primary liver cancer tissues, compared to matched distal tissues. TSPAN6 was strongly expressed in biliary epithelial cells, and to a lesser degree in hepatocytes within normal tissues and showed increased expression in the diseased state. In chronically diseased tissues, a strong association with the fibrotic septa was observed and we show that TSPAN6 strongly co-localised with cytokeratin 7, a marker of intermediary cells in the ductular reaction. TSPAN6-expressing cells were also in close association with aggregates of CD20+ B cells within diseased tissues. Primary liver cancer tumours showed variable expression of TSPAN6 and preliminary analysis in HCC tumours suggested a correlation between positive tumour TSPAN6 expression and better overall patient survival, over a 5 year period. Conclusions In this study, we have described, for the first time, the expression of TSPAN6 in human liver tissues. Chronically diseased liver tissues showed increased protein expression of TSPAN6 compared to normal tissues, and its expression was largely associated with the fibrotic septa and was in close proximity to B cell rich areas. TSPAN6 expression was highly variable between primary liver cancer tumour tissues, but increased expression was linked to higher patient survival. Our preliminary data suggest that TSPAN6 could play a role in the tumour microenvironment of primary liver cancers and further investigation is warranted.
Open AccessP176 TSPAN6: a novel player in the microenvironment of primary liver cancers
Introduction Tetraspanins, a large family of membrane proteins, have been implicated in the regulation of the tumour microenvironment of a number of cancers. TSPAN6 has previously been shown to modulate the immune microenvironment in breast cancers via indirect interactions with tumour-infiltrating B cells; however, TSPAN6 has not been studied within the context of primary liver cancers, nor the human liver in general. Methods TSPAN6 mRNA expression was quantified in normal, chronically diseased and primary liver cancer tissues. The distribution and cellular localisation of TSPAN6 protein expression was explored utilising immunohistochemistry and multi-colour immunofluorescence. In addition, hepatocellular carcinoma (HCC) tumour samples were histologically scored on intensity and proportion of positivity for TSPAN6 and Kaplan-Meier curves were generated for patients with negative/low expression vs. positive TSPAN6 tumour expression. Results Transcriptional expression of TSPAN6 was comparable between normal and chronically diseased liver tissues, but was increased in primary liver cancer tissues, compared to matched distal tissues. TSPAN6 was strongly expressed in biliary epithelial cells, and to a lesser degree in hepatocytes within normal tissues and showed increased expression in the diseased state. In chronically diseased tissues, a strong association with the fibrotic septa was observed and we show that TSPAN6 strongly co-localised with cytokeratin 7, a marker of intermediary cells in the ductular reaction. TSPAN6-expressing cells were also in close association with aggregates of CD20+ B cells within diseased tissues. Primary liver cancer tumours showed variable expression of TSPAN6 and preliminary analysis in HCC tumours suggested a correlation between positive tumour TSPAN6 expression and better overall patient survival, over a 5 year period. Conclusions In this study, we have described, for the first time, the expression of TSPAN6 in human liver tissues. Chronically diseased liver tissues showed increased protein expression of TSPAN6 compared to normal tissues, and its expression was largely associated with the fibrotic septa and was in close proximity to B cell rich areas. TSPAN6 expression was highly variable between primary liver cancer tumour tissues, but increased expression was linked to higher patient survival. Our preliminary data suggest that TSPAN6 could play a role in the tumour microenvironment of primary liver cancers and further investigation is warranted.
- Top Cited PapersOpen Access
- 2 September 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11
The Immunological Basis of Liver Allograft Rejection
Liver allograft rejection remains a significant cause of morbidity and graft failure in liver transplant recipients. Rejection is caused by the recognition of non-self donor alloantigens by recipient T-cells. Antigen recognition results in proliferation and activation of T-cells in lymphoid tissue before migration to the allograft. Activated T-cells have a variety of effector mechanisms including direct T-cell mediated damage to bile ducts, endothelium and hepatocytes and indirect effects through cytokine production and recruitment of tissue-destructive inflammatory cells. These effects explain the histological appearances of typical acute T-cell mediated rejection. In addition, donor specific antibodies, most typically against HLA antigens, may give rise to antibody-mediated rejection causing damage to the allograft primarily through endothelial injury. However, as an immune-privileged site there are several mechanisms in the liver capable of overcoming rejection and promoting tolerance to the graft, particularly in the context of recruitment of regulatory T-cells and promotors of an immunosuppressive environment. Indeed, around 20% of transplant recipients can be successfully weaned from immunosuppression. Hence, the host immunological response to the liver allograft is best regarded as a balance between rejection-promoting and tolerance-promoting factors. Understanding this balance provides insight into potential mechanisms for novel anti-rejection therapies.
- 2 September 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11
Top Cited PapersOpen AccessThe Immunological Basis of Liver Allograft Rejection
Liver allograft rejection remains a significant cause of morbidity and graft failure in liver transplant recipients. Rejection is caused by the recognition of non-self donor alloantigens by recipient T-cells. Antigen recognition results in proliferation and activation of T-cells in lymphoid tissue before migration to the allograft. Activated T-cells have a variety of effector mechanisms including direct T-cell mediated damage to bile ducts, endothelium and hepatocytes and indirect effects through cytokine production and recruitment of tissue-destructive inflammatory cells. These effects explain the histological appearances of typical acute T-cell mediated rejection. In addition, donor specific antibodies, most typically against HLA antigens, may give rise to antibody-mediated rejection causing damage to the allograft primarily through endothelial injury. However, as an immune-privileged site there are several mechanisms in the liver capable of overcoming rejection and promoting tolerance to the graft, particularly in the context of recruitment of regulatory T-cells and promotors of an immunosuppressive environment. Indeed, around 20% of transplant recipients can be successfully weaned from immunosuppression. Hence, the host immunological response to the liver allograft is best regarded as a balance between rejection-promoting and tolerance-promoting factors. Understanding this balance provides insight into potential mechanisms for novel anti-rejection therapies.
- 24 October 2017
- Published by Wiley in Histopathology
- Vol. 72 (2) , 339-341
Rapidly progressive intravascular primary effusion lymphoma in an HIV‐positive renal transplant recipient
We describe the clinical and post‐mortem findings of a case of rapidly progressive, ultimately fatal primary effusion lymphoma (PEL) arising in an HIV‐positive man 2 years after renal transplantation. Disseminated multi‐organ involvement associated with a peculiar intravascular pattern of growth, as seen in this case, has only been reported once previously. This is also, to our knowledge, the first detailed description of a lymphoma arising post‐transplant in an HIV‐positive patient.
- 24 October 2017
- Published by Wiley in Histopathology
- Vol. 72 (2) , 339-341
Rapidly progressive intravascular primary effusion lymphoma in an HIV‐positive renal transplant recipient
We describe the clinical and post‐mortem findings of a case of rapidly progressive, ultimately fatal primary effusion lymphoma (PEL) arising in an HIV‐positive man 2 years after renal transplantation. Disseminated multi‐organ involvement associated with a peculiar intravascular pattern of growth, as seen in this case, has only been reported once previously. This is also, to our knowledge, the first detailed description of a lymphoma arising post‐transplant in an HIV‐positive patient.